作者: C J Logothetis , M L Samuels , D Selig , D Swanson , D E Johnson
关键词:
摘要: Forty-eight patients with advanced nonseminomatous germ cell tumors of the testis received a combination cyclophosphamide, doxorubicin, and cisplatin (CISCAII) modified vinblastine bleomycin (VBIV) cyclic chemotherapy. Forty-four (92%) have achieved complete remission. No patient in remission has relapsed mean follow-up 139.0 weeks (SEM 7.0 weeks). The were stratified according to Samuels clinical staging criteria. Thirty-seven (77%) had disease (stage III-B3 III-B5), ten whom visceral non-lung III-B5). Chemotherapy was individualized by tumor volume response therapy. Two courses delivered after or development stable mass negative serum biomarkers. Twenty-four (50%) explored for persistent mass. viable cancer found; 15 (62%) mature teratomas nine (38%) scar. suffered from doxorubicin cardioto...